An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.

Trial Profile

An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors LIDDS
  • Most Recent Events

    • 30 Aug 2017 According to a Lidds Pharma media release, results from this and the LPC-003 trials have been published in The Journal of Urology.
    • 10 Jun 2017 Biomarkers information updated
    • 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top